Clivia Pharma Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 01-01-2025
- Paid Up Capital ₹ 0.10 M
as on 01-01-2025
- Company Age 14 Year, 4 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 2.00 Cr
as on 01-01-2025
- Revenue 35.65%
(FY 2023)
- Profit -24.56%
(FY 2023)
- Ebitda -158.57%
(FY 2023)
- Net Worth 24.61%
(FY 2023)
- Total Assets 69.47%
(FY 2023)
About Clivia Pharma
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹2.00 Cr.
Alwin George, Kizhakkiveettil Manojkumar, Benny Panakkal, and Two other members serve as directors at the Company.
- CIN/LLPIN
U51397KL2010PTC026644
- Company No.
026644
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
01 Sep 2010
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Ernakulam
Industry
Company Details
- Location
Ernakulam, Kerala, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Clivia Pharma?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Vasudevan Santhosh  | Managing Director | 01-Aug-2019 | Current |
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Alwin George | Director | 01-Aug-2019 | Current |
| Kizhakkiveettil Manojkumar | Director | 03-May-2017 | Current |
| Benny Panakkal | Director | 01-Aug-2019 | Current |
| Pradeep Pengattu | Director | 01-Aug-2019 | Current |
Financial Performance of Clivia Pharma.
Clivia Pharma Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 35.65% increase. The company also saw a substantial fall in profitability, with a 24.56% decrease in profit. The company's net worth Soared by an impressive increase of 24.61%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Clivia Pharma?
In 2023, Clivia Pharma had a public holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Mizzio 18 Marketing Solutions Private LimitedActive 6 years 9 monthsAlwin George is a mutual person
- Pharmacon Care Private LimitedActive 3 years 6 months
Kizhakkiveettil Manojkumar, Vasudevan Santhosh and 1 more are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 29 Jul 2023 | ₹2.00 Cr | Open |
How Many Employees Work at Clivia Pharma?
Unlock and access historical data on people associated with Clivia Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Clivia Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Clivia Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
